CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 6 (2025) Vis Cancer Med, 6 (2025) 9 References
Open Access
Issue
Vis Cancer Med
Volume 6, 2025
Article Number 9
Number of page(s) 11
DOI https://doi.org/10.1051/vcm/2025010
Published online 24 July 2025
  1. Haanen J, Los C, Phan GQ, et al. Adoptive cell therapy for solid tumors: current status in melanoma and next-generation therapies. American Society of Clinical Oncology Educational Book. 2024; 44(3):e431608. [Google Scholar]
  2. Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Frontiers in Immunology. 2021;12:690499. [Google Scholar]
  3. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68. [Google Scholar]
  4. Tang Y, Zhang AXJ, Chen G, et al. Prognostic and therapeutic TILs of cervical cancer – current advances and future perspectives. Molecular Therapy Oncolytics. 2021;22:410–430. [Google Scholar]
  5. Topalian SL, Rosenberg SA. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta Haematoligca. 1987;78(Suppl 1);75–76. [Google Scholar]
  6. Wang S, Sun J, Chen K, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors. BMC Medicine. 2021;19:140. [Google Scholar]
  7. Muul LM, Spiess PJ, Director EP, et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. Journal of immunology (Baltimore, Md.: 1950). 1987;138(3):989–995. [Google Scholar]
  8. Albarrán Fernández V, Ballestín Martínez P, Stoltenborg Granhøj J, et al. Biomarkers for response to TIL therapy: a comprehensive review. Journal for ImmunoTherapy of Cancer. 2024;12(3):e008640. [Google Scholar]
  9. Shoushtari AN, Powell DJ. Tumor-infiltrating lymphocyte therapy for melanoma and other solid tumors: looking back, yet moving forward. Transplantation and Cellular Therapy. 2025;31(3):S581–S590. [Google Scholar]
  10. Parums DV. First regulatory approval for adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs) – Lifileucel (Amtagvi). Medical Science Monitor. 2024;30:e944927. [Google Scholar]
  11. Chesney J, Lewis KD, Kluger H, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for ImmunoTherapy of Cancer. 2022;10(12):e005755. [Google Scholar]
  12. Zhu Y, Zhou J, Zhu L, et al. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human Vaccines and Immunotherapeutics. 2022;18(5):2060019. [Google Scholar]
  13. Piroozkhah M, Gholinezhad Y, Piroozkhah M, et al. The molecular mechanism of actions and clinical utilities of tumor infiltrating lymphocytes in gastrointestinal cancers: a comprehensive review and future prospects toward personalized medicine. Frontiers in Immunology. 2023;14:1298891. [Google Scholar]
  14. Yang J, Ding X, Fang Z, et al. Association of CD8+ TILs co-expressing granzyme A and interferon-γ with colon cancer cells in the tumor microenvironment. BMC Cancer. 2024;24(1):869. [Google Scholar]
  15. Betof Warner A, Corrie PG, Hamid O. Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clinical Cancer Research. 2023;29(10):1835–1854. [Google Scholar]
  16. Turcotte S, Donia M, Gastman B, et al. Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010207. [Google Scholar]
  17. Zhao Y, Deng J, Rao S, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14(17):4160. [Google Scholar]
  18. Mullinax JE, Hall M, Prabhakaran S, et al. Combination of ipilimumab and adoptive cell therapy with tumor-infiltrating lymphocytes for patients with metastatic melanoma. Frontiers in Oncology. 2018;8:44. [Google Scholar]
  19. Vafaei S, Zekiy AO, Khanamir RA, et al. Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International. 2022;22:1–27. [Google Scholar]
  20. Chamberlain CA, Bennett EP, Kverneland AH, et al. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Molecular Therapy Oncolytics. 2022;24:417–428. [Google Scholar]
  21. Amaria RN, McQuade JL, Davies MA, et al. OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma. Journal of Clinical Oncology. 2024;42:9515–9515. [Google Scholar]
  22. Peng W, Ye Y, Rabinovich BA, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clinical Cancer Research. 2010;16(22):5458–5468. [Google Scholar]
  23. Creelan BC, Wang C, Teer JK, et al. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nature Medicine. 2021;27(8):1410–1418. [Google Scholar]
  24. Stevanović S, Draper LM, Langhan MM, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. Journal of Clinical Oncology. 2015;33(14):1543–1550. [Google Scholar]
  25. Stevanović S, Pasetto A, Helman SR, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200–205. [Google Scholar]
  26. Stevanović S, Helman SR, Wunderlich JR, et al. A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers. Clinical Cancer Research. 2019;25(5):1486–1493. [Google Scholar]
  27. Lowery FJ, Goff SL, Gasmi B, et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial. Nature Medicine. 2025;31:1994–2003. [Google Scholar]
  28. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–645. [Google Scholar]
  29. Lievense JJ, Nijenhuis C, Jedema I, et al. Defining the quality attributes for tumor-infiltrating lymphocyte medicinal products. Transplantation and Cellular Therapy. 2025;31(3):S610–S625. [Google Scholar]
  30. Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research. 2012;18(24):6758–6770. [Google Scholar]
  31. Kverneland AH, Chamberlain CA, Borch TH, et al. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. Journal for ImmunoTherapy of Cancer. 2021;9(10):e003499. [Google Scholar]
  32. Hall MS, Teer JK, Yu X, et al. Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. Journal for ImmunoTherapy of Cancer. 2023;11(10):e007288. [Google Scholar]
  33. Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596(7870):119–125. [Google Scholar]
  34. Simoni Y, Becht E, Fehlings M, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575–579. [Google Scholar]
  35. Jansen CS, Prokhnevska N, Master VA, et al. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature. 2019;576:465–470. [Google Scholar]
  36. Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175(4):998–1013.e20. [CrossRef] [PubMed] [Google Scholar]
  37. Huang J, Khong HT, Dudley ME, et al. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. Journal of Immunotherapy. 2005;28(3):258–267. [Google Scholar]
  38. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research. 2011;17(13):4550–4557. [Google Scholar]
  39. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of immunology. 2005;175(10):7046–7052. [Google Scholar]
  40. Gattinoni L, Klebanoff CA, Palmer DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation. 2005;115(6):1616–1626. [Google Scholar]
  41. Tran KQ, Zhou J, Durflinger KH, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. Journal of Immunotherapy. 2008;31(8):742–751. [Google Scholar]
  42. Donia M, Junker N, Ellebaek E, et al. Characterization and comparison of “Standard” and “young” tumour‐infiltrating lymphocytes for adoptive cell therapy at a Danish Translational research institution. Scandinavian Journal of Immunology. 2012;75(2):157–167. [Google Scholar]
  43. Chiffelle J, Barras D, Pétremand R, et al. Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity, 2024;51(10):2466–2482. [Google Scholar]
  44. Zhou X, Wu J, Duan C, et al. Retrospective analysis of adoptive TIL therapy plus anti‐PD1 therapy in patients with chemotherapy‐resistant metastatic osteosarcoma. Journal of Immunology Research. 2020;2020(1):7890985. [Google Scholar]
  45. Liu XF, Song B, Sun CB, et al. Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma. Cell Reports Medicine. 2025;6(5):102096. [Google Scholar]
  46. Dafni U, Michielin O, Lluesma SM, et al. Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology. 2019;30(12):1902–1913. [Google Scholar]
  47. Sarnaik AA, Hamid O, Khushalani NI, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. Journal of Clinical Oncology. 2021;39(24):2656–2666. [Google Scholar]
  48. Nguyen LT, Yen PH, Nie J, et al. Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One. 2010;5(11):e13940. [Google Scholar]
  49. van den Berg JH, Heemskerk B, van Rooij N, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. Journal for ImmunoTherapy of Cancer. 2020;8(2):e000848. [Google Scholar]
  50. Besser MJ, Itzhaki O, Ben‐Betzalel G, et al. Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. Molecular Carcinogenesis. 2020;59(7):736–744. [Google Scholar]
  51. Albarrán V, San Román M, Pozas J, et al. Adoptive T cell therapy for solid tumors: current landscape and future challenges. Frontiers in Immunology. 2024;15:1352805. [Google Scholar]
  52. Joerger M, Calvo E, Laubli H, et al. Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for ImmunoTherapy of Cancer. 2023;11(11):e007784. [Google Scholar]
  53. Sarnaik AA, Hwu P, Mulé JJ, et al. Tumor-infiltrating lymphocytes: a new hope. Cancer Cell. 2024;42(8):1315–1318. [Google Scholar]
  54. Zhang L, Morgan RA, Beane JD, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clinical Cancer Research. 2015;21(10):2278–2288. [Google Scholar]
  55. Betof Warner A, Hamid O, Komanduri K, et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. Journal for ImmunoTherapy of Cancer. 2024;12(2):e008735. [Google Scholar]
  56. Heimann A. Elongated T cell expansion by utilizing IL7 and IL15 leads to increased T cell yield while preserving Tcm/Tscm characteristics feasible for adoptive T cell therapy. Germany: Freie Universitaet Berlin; 2020. [Google Scholar]
  57. Pilipow K, Roberto A, Roederer M, et al. IL15 and T-cell stemness in T-cell-based cancer immunotherapy. Cancer Research. 2015;75(24):5187–5193. [Google Scholar]
  58. Leonard-Murali S, Kammula US. Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma. Immunotherapy. 2025;17(4):283–291. [Google Scholar]
  59. Lowery FJ, Krishna S, Yossef R, et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science. 2022;375(6583):877–884. [Google Scholar]
  60. Ye Q, Song DG, Poussin M, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clinical Cancer Research. 2014;20(1):44–55. [Google Scholar]
  61. Eiva MA, Omran DK, Chacon JA, et al. Systematic analysis of CD39, CD103, CD137, and PD‐1 as biomarkers for naturally occurring tumor antigen‐specific TILs. European Journal of Immunology. 2022;52(1):96–108. [Google Scholar]
  62. Tavera RJ, Forget MA, Kim YU, et al. Utilizing T-cell activation signals 1, 2, and 3 for tumor-infiltrating lymphocytes (TIL) expansion: the advantage over the sole use of interleukin-2 in cutaneous and uveal melanoma. Journal of Immunotherapy. 2018;41(9):399–405. [Google Scholar]
  63. Matsueda S, Chen L, Li H, et al. Recent clinical researches and technological development in TIL therapy. Cancer Immunology, Immunotherapy. 2024;73(11):232. [Google Scholar]
  64. Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nature Communications. 2018;9(1):2724. [Google Scholar]
  65. Kim Y, Shin Y, Kang GH. Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis. Scientific Reports. 2019;9(1):3808. [Google Scholar]
  66. Franciszkiewicz K, Le Floch A, Boutet M, et al. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Research. 2013;73(2):617–628. [Google Scholar]
  67. Li D, Chen C, Li J, et al. A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8+ T cell therapy in patients with advanced solid tumors. Nature Communications. 2023;14(1):3447. [Google Scholar]
  68. Fix SM, Forget MA, Sakellariou-Thompson D, et al. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. Journal for ImmunoTherapy of Cancer. 2022;10(7):e003750. [Google Scholar]
  69. Lou E, Choudhry MS, Starr TK, et al. Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial. Lancet Oncology. 2025;26(5):559–570. [Google Scholar]
  70. Conlon KC, Lugli E, Welles HC, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of Clinical Oncology. 2015;33(1):74–82. [Google Scholar]
  71. Goff SL, Dudley ME, Citrin DE, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. Journal of Clinical Oncology. 2016;34(20):2389–2397. [Google Scholar]
  72. Guo J, Wang C, Luo N, et al. IL-2-free tumor-infiltrating lymphocyte therapy with PD-1 blockade demonstrates potent efficacy in advanced gynecologic cancer. BMC Medicine. 2024;22(1):207. [Google Scholar]
  73. Lickefett B, Chu L, Ortiz-Maldonado V, et al. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Frontiers in Immunology. 2023;14:1303935. [Google Scholar]
  74. Verdegaal EM, Verpoorte ALC, van der Kooij MK, et al. Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires IFNα. Clinical Cancer Research. 2025;31:2628–2638. [Google Scholar]
  75. Friese C, Harbst K, Borch TH, et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer. Scientific Reports. 2020;10(1):3914. [Google Scholar]
  76. Martinez-Usatorre A, Carmona SJ, Godfroid C, et al. Enhanced phenotype definition for precision isolation of precursor exhausted tumor-infiltrating CD8 T cells. Frontiers in Immunology. 2020;11:340. [Google Scholar]
  77. Kristensen NP, Heeke C, Tvingsholm SA, et al. Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma. Journal of Clinical Investigation. 2022;132(2):e150535. [Google Scholar]
  78. Levi ST, Copeland AR, Nah S, et al. Neoantigen identification and response to adoptive cell transfer in anti-PD-1 naïve and experienced patients with metastatic melanoma. Clinical Cancer Research. 2022;28(14):3042–3052. [Google Scholar]
  79. Yuhas A, Dean J, Erickson T, et al. Effect of a novel expansion process on tumor-infiltrating lymphocyte (TIL) polyfunctionality, cytotoxicity, and expansion, while preserving cells in a less differentiated and more stem-like phenotype. Journal of Clinical Oncology. 2023;41:2542–2542. [Google Scholar]
  80. Turcotte S, Gros A, Hogan K, et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. Journal of Immunology. 2013;191(5):2217–2225. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.